INCY vs. WST: Incyte vs. West Pharmaceutical Services Stock Comparison
How do Incyte (INCY) and West Pharmaceutical Services (WST) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Incyte (INCY) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but INCY is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.
| Profile Item | INCY | WST |
|---|---|---|
| Name | Incyte Corp. | West Pharmaceutical Services Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 24.39 billion USD | 27.85 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | November 4, 1993 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | INCY | WST |
|---|---|---|
| Total Return (1Y) | 14.06% | 51.68% |
| Total Return (3Y, Annualized) | 32.03% | 7.13% |
| Total Return (5Y, Annualized) | 12.69% | 0.05% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | INCY | WST |
|---|---|---|
| Volatility (1Y, Annualized) | 33.19% | 31.45% |
| Beta (5Y) | 0.78 | 1.13 |
| Max Drawdown (5Y) | -40.50% | -59.29% |
| Avg. Volume (3M) | 1.58M | 603.86K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | INCY | WST |
|---|---|---|
| Sharpe Ratio (1Y) | 0.29 | 1.51 |
| Sortino Ratio (1Y) | 0.46 | 2.35 |
Profitability
ROE (TTM)
Both Incyte (INCY) at 7.84% and West Pharmaceutical Services (WST) at 21.23% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.84%
- Max
- 109.18%
- INCY
- 7.84%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.23%
- Max
- 109.18%
- WST
- 21.23%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
West Pharmaceutical Services (WST) at 18.81% keeps the most of each sales dollar — above its industry’s net margin range — and Incyte (INCY) at 6.71% also retains a top-quartile share.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.71%
- Max
- 18.05%
- INCY
- 6.71%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.81%
- WST
- 18.81%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Incyte (INCY) at 33.72% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.72%
- Max
- 83.12%
- INCY
- 33.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.37%
- Max
- 83.12%
- WST
- 25.37%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | INCY | WST |
|---|---|---|
| ROE (TTM) | 7.84% | 21.23% |
| ROA (TTM) | 17.78% | 11.89% |
| Net Margin (TTM) | 6.71% | 18.81% |
| Operating Margin (TTM) | 33.72% | 25.37% |
| Gross Margin (TTM) | 56.02% | 37.59% |
Growth
Revenue Growth
Both Incyte (INCY) at 21.22% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Incyte (INCY) at 4,173.33% clears its industry range for EPS growth, a much stronger earnings trajectory than West Pharmaceutical Services (WST) at 1.49%, which is closer to a typical peer reading.
Growth Metrics
| Metric | INCY | WST |
|---|---|---|
| Revenue Growth (YoY) | 21.22% | 6.25% |
| Revenue Growth (3Y CAGR) | 14.84% | 2.12% |
| EPS Growth (YoY) | 4,173.33% | 1.49% |
| EPS Growth (3Y CAGR) | 61.56% | -4.23% |
Financial Strength
Current Ratio (MRQ)
Both Incyte (INCY) at 3.84 and West Pharmaceutical Services (WST) at 2.82 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.84
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- INCY
- 3.84
- Q1
- 2.47
- Min
- 0.10
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- WST
- 2.82
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Incyte (INCY) at 0.01 keeps leverage in the lower industry quartile, while West Pharmaceutical Services (WST) at 0.11 runs a more typical debt-to-equity mix.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- INCY
- 0.01
- Min
- 0.00
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.11
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- WST
- 0.11
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | INCY | WST |
|---|---|---|
| Current Ratio (MRQ) | 3.84 | 2.82 |
| Debt / Equity (MRQ) | 0.01 | 0.11 |
| Net Debt / EBITDA | -1.88 | -0.16 |
Dividends
Dividend Yield (TTM)
Incyte (INCY) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.22%
- WST
- 0.22%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Incyte (INCY) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- INCY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88%
- WST
- 9.88%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | INCY | WST |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.22% |
| Dividend Payout Ratio (TTM) | 0.00% | 9.88% |
Valuation
P/E Ratio (TTM)
Both Incyte (INCY) at 61.05 and West Pharmaceutical Services (WST) at 44.87 sit in the richer earnings-multiple quartile for P/E ratio, so investors are paying more for TTM earnings than they pay for typical peers.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
61.05
- Max
- 85.34
- INCY
- 61.05
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
44.87
- Max
- 85.34
- WST
- 44.87
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Incyte (INCY) at 4.06 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.06
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- INCY
- 4.06
- Q1
- 3.01
- Min
- 0.01
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20
- Max
- 58.18
- Q3
- 25.77
- WST
- 8.20
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Incyte (INCY) at 4.33 is valued about in line with its industry on P/B ratio, while West Pharmaceutical Services (WST) at 9.40 carries an above-peer premium to book — WST is pricier on assets.
INCY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.33
- Max
- 13.53
- Q3
- 6.54
- INCY
- 4.33
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
WST
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.40
- Max
- 13.53
- WST
- 9.40
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | INCY | WST |
|---|---|---|
| P/E Ratio (TTM) | 61.05 | 44.87 |
| P/S Ratio (TTM) | 4.06 | 8.20 |
| P/B Ratio (MRQ) | 4.33 | 9.40 |
| Free Cash Flow Yield (TTM) | 5.28% | 1.24% |